Positive HER2 status - Is it a discriminating factor for disease outcome in steroid receptor-positive early breast cancer patients treated with adjuvant endocrine therapy only?

被引：1
|
作者：
Susnjar, S. [1 ]
Vujasinovic, T. [2 ]
Abu Rabi, Z. [2 ]
Neskovic-Konstantinovic, Z. [1 ]
Milovanovic, Z. [3 ]
Jovanovic, D. [3 ]
Gavrilovic, D. [4 ]
Borojevic, N. [5 ]
机构：
[1] Inst Oncol & Radiol Serbia, Dept Med Oncol, Belgrade, Serbia
[2] Inst Oncol & Radiol Serbia, Expt Oncol Lab, Belgrade, Serbia
[3] Inst Oncol & Radiol Serbia, Dept Pathol, Belgrade, Serbia
[4] Inst Oncol & Radiol Serbia, Ctr Data, Belgrade, Serbia
[5] Inst Oncol & Radiol Serbia, Dept Radiotherapy, Belgrade, Serbia
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(10)70187-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：103 / 104
页数：2
相关论文
共 50 条
  • [41] THE UPFRONT THERAPY FOR HER2 POSITIVE BREAST CANCER PATIENTS
    Iwata, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 76 - 76
  • [42] Association of Endocrine Therapy with Survival for Patients with Small, Hormone Receptor-Positive, HER2-Negative, Breast Cancer
    Ma, S. J.
    Oladeru, O. T.
    Sood, A. J.
    Mikucki, M.
    Farrugia, M. K.
    Singh, A. K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E74 - E74
  • [43] HER2 status in breast cancer patients: A comparison between borderline positive HER2 and strongly positive HER2 tumors
    Huszno, J.
    Nowara, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S137 - S137
  • [44] Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)- Positive Early Breast Cancer
    Karly P. Garnock-Jones
    Gillian M. Keating
    Lesley J. Scott
    BioDrugs, 2010, 24 : 207 - 209
  • [45] Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
    Garnock-Jones, Karly P.
    Keating, Gillian M.
    Scott, Lesley J.
    BIODRUGS, 2010, 24 (03) : 207 - 209
  • [46] Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity
    Frassoldati, Antonio
    Biganzoli, Laura
    Bordonaro, Roberto
    Cinieri, Saverio
    Conte, Pierfranco
    De Laurentis, Michelino
    Del Mastro, Lucia
    Gori, Stefania
    Lauria, Rossella
    Marchetti, Paolo
    Michelotti, Andrea
    Montemurro, Filippo
    Naso, Giuseppe
    Pronzato, Paolo
    Puglisi, Fabio
    Tondini, Carlo Alberto
    FUTURE ONCOLOGY, 2020, 16 (05) : 129 - 145
  • [47] Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer
    Tevaarwerk, Amye J.
    Wisinski, Kari B.
    O'Regan, Ruth M.
    JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (11) : 1148 - +
  • [48] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Kurebayashi, Junichi
    Kanomata, Naoki
    Yamashita, Tetsumasa
    Shimo, Toshiro
    Mizutoh, Akiko
    Moriya, Takuya
    Sonoo, Hiroshi
    BREAST CANCER, 2015, 22 (03) : 292 - 299
  • [49] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Junichi Kurebayashi
    Naoki Kanomata
    Tetsumasa Yamashita
    Toshiro Shimo
    Akiko Mizutoh
    Takuya Moriya
    Hiroshi Sonoo
    Breast Cancer, 2015, 22 : 292 - 299
  • [50] Alternative targeted therapy for early Her2 positive breast cancer
    Harvey, Sandra L.
    Khasraw, Mustafa
    GLAND SURGERY, 2013, 2 (01) : 42 - 45
12345